-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

Benzinga·10/05/2026 13:00:02
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.